3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
55
Leukemia, Myeloid, Acute
38
Breast Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
35
Multiple Myeloma
31
Lymphoma, Non-Hodgkin
29
Burkitt Lymphoma
29
Lymphoma
27
Myelodysplastic Syndromes
25
Triple Negative Breast Neoplasms
23
Recurrence
23
Hematologic Neoplasms
22
Lymphoma, B-Cell
21
Lymphoma, Follicular
20
Melanoma
16
Ovarian Neoplasms
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Neoplasm Metastasis
14
Leukemia
14
Hodgkin Disease
13
Neoplasms
12
Leukemia, Biphenotypic, Acute
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Neuroblastoma
11
Leukemia, Myelomonocytic, Chronic
11
Lymphoma, Mantle-Cell
10
Graft vs Host Disease
10
Carcinoma, Non-Small-Cell Lung
10
Lymphoma, T-Cell, Peripheral
9
Interventions
Bevacizumab
2
tislelizumab
1
fludarabine
1
codrituzumab
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Simpson-Golabi-Behmel syndrome
×
Cyclophosphamide
×
Clear all
NCT07500220
2026-03-30
DUET-HCC
Beijing Biotech
Phase 1/2
Recruiting
30 enrolled